Cargando…

In vivo imaging of tau deposition in Alzheimer’s disease using both [(18)F]-THK5317 and [(18)F]-S16: A pilot human study

OBJECTIVE: To evaluate the effectiveness of a new tracer (S)-1-(4-(6-(dimethylamino)quinoxalin-2-yl)phenoxy)-3-fluoropropan-2-ol ([(18)F]-S16), in distinguishing patients with AD from HCs. METHODS: Paired [(18)F]-S16 and [(18)F]-THK5317 scans were acquired in five patients with AD, six HCs, one subj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Liping, Zhang, Jinming, Zhou, Kaixiang, Zhang, Xiaojun, Xie, Hengge, Zhu, Mingwei, Cui, Mengchao, Wang, Ruimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459225/ https://www.ncbi.nlm.nih.gov/pubmed/36092808 http://dx.doi.org/10.3389/fnagi.2022.994750

Ejemplares similares

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease
por: Saint-Aubert, Laure, et al.
Publicado: (2016)

[(18)F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer’s disease
por: Chiotis, Konstantinos, et al.
Publicado: (2020)

Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [(18)F]THK5317 PET
por: Jonasson, My, et al.
Publicado: (2019)

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016)

Comparison of (18)F-T807 and (18)F-THK5117 PET in a Mouse Model of Tau Pathology
por: Brendel, Matthias, et al.
Publicado: (2018)

Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [(18)F]-S16 in Healthy Volunteers and Its Application in Assessment of Tau Pathology in Alzheimer’s Disease
por: Wang, Ying, et al.
Publicado: (2022)

Perfusion-Phase [(18)F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration
por: Brendel, Matthias, et al.
Publicado: (2017)

Functional Abnormality Associated With Tau Deposition in Alzheimer’s Disease – A Hybrid Positron Emission Tomography/MRI Study
por: Fu, Liping, et al.
Publicado: (2021)

Optimization and Biodistribution of [(11)C]-TKF, An Analog of Tau Protein Imaging Agent [(18)F]-THK523
por: Kong, Yanyan, et al.
Publicado: (2016)

(18)F-THK5351 PET Imaging in the Behavioral Variant of Frontotemporal Dementia
por: Nam, Gijin, et al.
Publicado: (2018)

[(18)F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment
por: Jeong, Hye Jin, et al.
Publicado: (2020)

(18)F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies
por: Ezura, Michinori, et al.
Publicado: (2021)

Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [(18)F]THK-5117 Positron Emission Tomography
por: Ishiki, Aiko, et al.
Publicado: (2015)

Analysis of amyloid and tau deposition in Alzheimer's disease using (11)C-Pittsburgh compound B and (18)F-THK 5351 positron emission tomography imaging
por: Chanisa, Chotipanich, et al.
Publicado: (2020)

Neuroimaging-pathological correlations of [(18)F]THK5351 PET in progressive supranuclear palsy
por: Ishiki, Aiko, et al.
Publicado: (2018)

Distinct [(18)F]THK5351 binding patterns in primary progressive aphasia variants
por: Schaeverbeke, Jolien, et al.
Publicado: (2018)

Longitudinal Assessment of Tau-Associated Pathology by (18)F-THK5351 PET Imaging: A Histological, Biochemical, and Behavioral Study
por: Moreno-Gonzalez, Ines, et al.
Publicado: (2021)

Tau PET With (18)F-THK-5351 Taiwan Patients With Familial Alzheimer's Disease With the APP p.D678H Mutation
por: Huang, Chin-Chang, et al.
Publicado: (2019)

Visualization of ischemic stroke-related changes on (18)F-THK-5351 positron emission tomography
por: Huang, Kuo-Lun, et al.
Publicado: (2018)

[(18)F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy
por: Brendel, Matthias, et al.
Publicado: (2018)

(18)F-THK5351 PET Imaging in Nonfluent-Agrammatic Variant Primary Progressive Aphasia
por: Yoon, Cindy W, et al.
Publicado: (2018)

Relationships between [(18)F]-THK5351 Retention and Language Functions in Primary Progressive Aphasia
por: Jeong, Hye Jin, et al.
Publicado: (2019)

Early brainstem ([18F])THK5351 uptake is linked to cortical hyperexcitability in healthy aging
por: Van Egroo, Maxime, et al.
Publicado: (2021)

High sensitivity of asymmetric (18)F-THK5351 PET abnormality in patients with corticobasal syndrome
por: Kurihara, Masanori, et al.
Publicado: (2023)

Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351
por: Lockhart, Samuel N., et al.
Publicado: (2016)

Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
por: Ng, Kok Pin, et al.
Publicado: (2017)

[(18)F]THK-5351 PET Patterns in Patients With Alzheimer’s Disease and Negative Amyloid PET Findings
por: Oh, Minyoung, et al.
Publicado: (2022)

Al(18)F-NODA Benzothiazole Derivatives as Imaging Agents for Cerebrovascular Amyloid in Cerebral Amyloid Angiopathy
por: Song, Jia, et al.
Publicado: (2018)

Error propagation analysis of seven partial volume correction algorithms for [(18)F]THK-5351 brain PET imaging
por: Oyama, Senri, et al.
Publicado: (2020)

(18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
por: Hsu, Jung-Lung, et al.
Publicado: (2020)

Discovery and development of brain-penetrant (18)F-labeled radioligands for neuroimaging of the sigma-2 receptors
por: Zhang, Ying, et al.
Publicado: (2022)

Comparison of New Tau PET-Tracer Candidates With [(18)F]T808 and [(18)F]T807
por: Declercq, Lieven, et al.
Publicado: (2016)

Voxel-based correlation of (18)F-THK5351 accumulation and gray matter volume in the brain of cognitively normal older adults
por: Shigemoto, Yoko, et al.
Publicado: (2019)

Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy
por: Ng, Kok Pin, et al.
Publicado: (2019)

(18)F–THK–5351, Fluorodeoxyglucose, and Florbetaben PET Images in Atypical Alzheimer’s Disease: A Pictorial Insight into Disease Pathophysiology
por: Park, Sohee, et al.
Publicado: (2021)

Voxel-based correlation of (18)F-THK5351 accumulation with gray matter structural networks in cognitively normal older adults
por: Shigemoto, Yoko, et al.
Publicado: (2021)

Author Correction: (18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
por: Hsu, Jung-Lung, et al.
Publicado: (2021)

Gray matter structural networks related to (18)F-THK5351 retention in cognitively normal older adults and Alzheimer's disease patients
por: Shigemoto, Yoko, et al.
Publicado: (2021)

(18)F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β-Amyloid-Negative Amnestic Mild Cognitive Impairment
por: Chun, Min Young, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rp8gs8fe51cqt88umsn2es5kn6